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AbsTrACT
Objective We have previously described a prognostic 
transcriptional signature in cD8 t cells that separates 
patients with iBD into two phenotypically distinct 
subgroups, termed iBD1 and iBD2. Here we sought to 
develop a blood-based test that could identify these 
subgroups without cell separation, and thus be suitable 
for clinical use in crohn’s disease (cD) and ulcerative 
colitis (Uc).
Design Patients with active iBD were recruited before 
treatment. transcriptomic analyses were performed on 
purified cD8 t cells and/or whole blood. Phenotype 
data were collected prospectively. iBD1/iBD2 patient 
subgroups were identified by consensus clustering 
of cD8 t cell transcriptomes. in a training cohort, 
machine learning was used to identify groups of genes 
(’classifiers’) whose differential expression in whole 
blood recreated the iBD1/iBD2 subgroups. genes from 
the best classifiers were quantitative (q)Pcr optimised, 
and further machine learning was used to identify the 
optimal qPcr classifier, which was locked down for 
further testing. independent validation was sought in 
separate cohorts of patients with cD (n=66) and Uc 
(n=57).
results in both validation cohorts, a 17-gene qPcr-
based classifier stratified patients into two distinct 
subgroups. irrespective of the underlying diagnosis, 
iBDhi patients (analogous to the poor prognosis iBD1 
subgroup) experienced significantly more aggressive 
disease than iBDlo patients (analogous to iBD2), 
with earlier need for treatment escalation (hazard 
ratio=2.65 (cD), 3.12 (Uc)) and more escalations 
over time (for multiple escalations within 18 months: 
sensitivity=72.7% (cD), 100% (Uc); negative predictive 
value=90.9% (cD), 100% (Uc)).
Conclusion this is the first validated prognostic 
biomarker that can predict prognosis in newly diagnosed 
patients with iBD and represents a step towards 
personalised therapy.
InTrODuCTIOn
In recent years, there has been a growing realisation 
that the future of IBD management needs to incor-
porate a personalised approach to therapy, in which 
the right treatment can be given to the right patient 
at the right time.1 This now represents a key goal 
in IBD and was recently named as one of the most 
important research priorities by the James Lind 
Alliance priority-setting partnership2—a group 
of clinicians, patients and other stakeholders who 
sought to identify important areas of unmet need. 
In truth, this ambition is shared across many disease 
areas, motivated by developments in oncology 
where personalised therapy has been achieved 
using biomarkers that can accurately predict cancer 
outcome and response to therapy.3 4 The poten-
tial advantages of personalised medicine in IBD 
significance of this study
What is already known about this subject?
 ► The course of Crohn’s disease (CD) and UC 
varies considerably between patients, but 
reliable prognostic markers are not available 
in clinical practice. This hinders disease 
management because treatment approaches 
that would be optimal for patients with 
indolent disease—characterised by infrequent 
flare-ups that can be readily controlled by 
first-line therapy— will inevitably undertreat 
those with progressive disease. Conversely, 
strategies that would appropriately control 
frequently relapsing, progressive disease will 
expose patients with more quiescent disease 
to the risks and side effects of unnecessary 
treatment. We have previously described a 
CD8 T cell gene expression signature that 
corresponds to differences in T cell exhaustion, 
is detectable during active untreated disease 
(including at diagnosis) and predicts disease 
course in both UC and CD. However, the need 
for cell separation and microarray-based gene 
expression analysis would make this difficult to 
translate to clinical practice.
What are the new findings?
 ► We have developed, optimised and 
independently validated a whole blood qPCR-
based classifier—designed to identify the 
IBD1 and IBD2 patient subgroups—that can 
reliably predict prognosis in patients with CD 
or UC from diagnosis without the need for 
cell separation. We also present a detailed 
phenotypic update on the disease course 
experienced by patients in either the IBD1/IBDhi 
or IBD2/IBDlo subgroups, incorporating both 
expanded patient cohorts and substantially 
longer follow-up. This affords new insights into 
the spectrum of therapies that are differentially 
required in these patient subgroups and 
reinforces their association with disease 
prognosis.
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are clear. First, this would anticipate the marked variability in 
prognosis that occurs between patients5 6 and which means that 
‘one-size-fits-all’ approaches cannot optimally treat everyone 
(either because they are ineffective in some or unnecessarily 
risky in others). Second, it would enable clinicians to better 
use the growing armamentarium of IBD therapies to improve 
clinical outcomes.7 For example, it is well recognised that early 
use of combination therapy (anti-tumour necrosis factor (TNF)
α monoclonal antibodies and an immunomodulator) is one of 
the most effective treatments in CD,8 particularly when given 
early in the disease course,9 10 but that indiscriminate use of 
this strategy would be prohibitively expensive and expose many 
patients to side effects of drugs that they do not require. Unfor-
tunately, in IBD—as in most autoimmune and inflammatory 
diseases—biomarkers that can reliably predict disease course 
from diagnosis are not available, precluding the delivery of 
personalised therapy.
We have previously reported that hypothesis-free inspection 
of CD8 T cell gene expression data from patients with active, 
untreated autoimmune disease can identify thousands of genes 
whose differential expression defines two distinct patient 
subgroups.11 12 Notably, these subgroups were not detectable 
using unsupervised analysis of unseparated peripheral blood 
mononuclear cells (PBMCs) from the same patients.11 12 In all 
of the diseases studied, including CD and UC, these subgroups 
were clinically indistinguishable at enrolment, but patients 
within them subsequently experienced contrasting disease 
courses, characterised by differences in the time to first relapse 
and the number of treatment escalations required over time.11 12 
More recent work has ascribed the gene signature to inter-pa-
tient differences in T cell exhaustion13: the phenomenon by 
which effector T cells progressively lose their ability to respond 
to target antigens. T cell exhaustion was originally reported as 
a consequence of chronic viral infection14 but is now recognised 
to occur with persistent auto-antigens.13 15 Consistent with being 
less able to respond to disease-related antigens, patients with 
more T cell exhaustion had a better prognosis, characterised by 
a longer time to disease relapse and fewer flares over time.13
Here, we describe how we have developed, optimised and 
independently validated a whole blood biomarker—designed 
to identify the IBD1/IBD2 subgroups—that can predict the 
course of UC and CD from diagnosis. Additionally, we present a 
detailed phenotypic update regarding the clinical consequences 
of being in the IBD1 (exhaustion low) or IBD2 (exhaustion high) 
subgroups.
MATerIAls AnD MeThODs
Patient recruitment (training cohort for biomarker discovery 
and CD8 T cell cohort—Cambridge)
Patients with active CD and UC, who were not receiving 
concomitant corticosteroids, immunomodulators or biological 
therapy, were recruited from a specialist IBD clinic at Adden-
brooke’s hospital, Cambridge, before commencing treatment. A 
stable dose of topical or oral 5-ASA was permitted if patients had 
been diagnosed previously. All subjects were recruited between 
2008 and 2014 and were aged 18 years or older. Most (86/118) 
were recruited at the time of diagnosis. All patients were diag-
nosed with CD or UC based on standard endoscopic, histolog-
ical and radiological criteria and were treated in accordance with 
national and international guidelines using a conventional step-up 
strategy within the UK National Health Service. Disease activity 
was assessed by considering symptoms, clinical signs, blood tests 
(C reactive protein, haemoglobin and albumin), stool markers 
(calprotectin) and endoscopic assessment where indicated. To be 
enrolled, patients had to have active disease confirmed by one or 
more objective marker (raised CRP, raised calprotectin or endo-
scopic evidence of active disease) in addition to active symptoms 
and/or signs (table 1). Clinicians were blinded to the biomarker 
results. Detailed phenotype data were collected prospectively. 
All participants provided written informed consent.
sample preparation
A 110 mL venous blood sample was taken from patients at enrol-
ment. PBMCs were immediately extracted and CD8 T cells were 
positively selected, as described previously.16 Following purifi-
cation, cells were lysed and lysates stored at −80°C. RNA was 
subsequently extracted using RNeasy Mini Kits (Qiagen) and 
quantified using a NanoDrop1000 Spectrophotometer (Ther-
moFisher). Of the total blood draw, 2.5 mL were collected into a 
PAXgene Blood RNA tube IVD (PreAnalytix), which was stored 
at −80°C. Whole blood RNA was subsequently extracted using 
a PAXgene 96 Blood RNA kit (PreAnalytix) according to the 
manufacturer’s instructions.
Microarray processing and analysis
Following assessment of RNA quality (2100 Bioanalyzer, Agilent 
Technologies), 200 ng RNA was processed for hybridisation onto 
Affymetrix Human Gene 1.0 ST microarrays (CD8 T cell samples, 
n=118) or Affymetrix Human Gene 2.0 ST microarrays (whole 
blood samples, n=69) according to the manufacturer’s instruc-
tions. Raw data were preprocessed (background corrected, 
normalised, quality checked and batch normalised) using Biocon-
ductor packages (http://www. bioconductor. org/) in R (http://
www. r- project. org/): affy,17 vsn,18 arrayQualityMetrics19 and 
sva.20 For CD8 T cell data, unsupervised consensus clustering 
was performed to identify the IBD1/IBD2 subgroups, as previ-
ously described.12 Of note, IBD1/IBD2 status was not included 
as a covariate in the batch normalisation of whole blood samples 
to reduce any downward bias in estimating the generalisation 
error during leave-one-out cross-validation (LOOCV).
biomarker development
Following preprocessing, a statistical (machine) learning 
method—logistic regression with an adaptive Elastic-Net 
penalty21 —was applied to the whole blood transcriptomic data 
to identify genes that could be used to calculate the probability 
of an individual belonging to the IBD1/IBD2 subgroups. Penal-
ised regression methods are a useful tool to regularise models, 
and thus control overfitting, during biomarker discovery.22 The 
adaptive Elastic-Net method in particular combines the strengths 
of the ridge penalty and the adaptively weighted lasso shrinkage 
penalty and can address the technical challenges in these data.21 
These were: high dimensionality (ie, number of samples is 
substantially smaller than number of genes), multicollinearity 
significance of this study
how might it impact on clinical practice in the foreseeable 
future?
 ► The qPCR-based classifier has performance characteristics 
that compare favourably with prognostic biomarkers 
currently in use in oncology and should be sufficient to 
guide therapy from diagnosis in patients with CD or UC. This 
represents an important step towards personalised therapy 
in IBD.
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(ie, expression of many genes is correlated, with the need to 
avoid selecting multiple correlated genes in the model) and 
requirement for a sparse and interpretable model (ie, need for 
a limited number of genes in a classifier in which the contribu-
tion of each can be interpreted). The initial model was deter-
mined using a classic Elastic-Net (implemented in the gcdnet 
package23 in R) followed by adaptive Elastic-Net training using 
equations reported in the original description of the method.21 
In brief, the optimal classification rule to identify the IBD1/IBD2 
subgroups was learnt from the whole blood microarray data by 
defining many different combinations of model hyperparame-
ters, which were then used to fit a corresponding number of 
candidate models (2100) to the whole blood expression data. 
Model selection was performed using the Bayesian Information 
Criterion (BIC), where the highest BIC corresponds to the best 
model (online supplementary table 1). BIC was defined as:
 
 
BIC = − ln
(
Lˆ
)
− k · ln (n)
 
 (n)
where k=degrees of freedom (the number of genes incorpo-
rated), n=number of samples and (L)=log likelihood function 
for the model. The generalisation error of the selected model 
was estimated using nested LOOCV.24
qPCr classifier development
A list of 39 candidate and 3 reference genes was taken forward 
to qPCR classifier development using TaqMan gene expression 
assays (online supplementary table 2). Following reverse tran-
scription of whole blood RNA, qPCR was performed in triplicate 
using a Roche LightCycler 480, and transcript abundance was 
calculated using the ΔΔCT method, based on the mean of tech-
nical replicates. The correlation between microarray and qPCR 
expression values was then used to filter the candidate gene 
list (six were removed due to poor correlation). This resulted 
in a dataset containing expression values for 33 candidate and 
3 reference genes from 69 samples. Following normalisation 
by feature standardisation, an identical penalised regression 
strategy was applied to this qPCR dataset to identify an optimal 
classification model comprising 16 informative and 2 reference 
genes. To refine this model for use on unscaled data, a prerequi-
site for use in a clinical setting, an additional round of penalised 
logistic regression was applied using the cvglmnet function in 
the glmnet package22 in R. This uses iterative cross-validation 
undertaken concurrently to facilitate automatic identification of 
the optimal, or most regularised, model (using accuracy of IBD1/
IBD2 classification as a performance metric). This identified a 
17-gene model (15 informative and 2 reference genes) with an 
error within 1 SE of the minimum mean cross-validated error, 
which was considered the most regularised (as recommended 
by the authors of this approach22). This 17-gene classifier was 
‘locked-down’ so that no further changes could be made and 
was then tested in the validation cohorts. Patients in the qPCR 
subgroup analogous to IBD1 were termed ‘IBDhi’ and patients 
in the subgroup analogous to IBD2 were termed ‘IBDlo’.
Validation cohorts
One hundred and twenty-three patients with active IBD (66 
CD, 57 UC) were recruited before commencing treatment from 
specialist clinics in four UK teaching hospitals (in Cambridge, 
Nottingham, Exeter and London). All subjects were recruited 
between 2009 and 2017 and were aged 18 years or older. The 
median follow-up was 1.9 years (IQR: 1.3–3.2 years). Of these 
patients, 115 (93%) were newly diagnosed (61 CD, 54 UC). 
Prospective follow-up data were collected for all patients, who 
were treated at the discretion of their gastroenterologists in 
accordance with national and international guidelines. Clini-
cians were blinded to gene expression analyses. From each 
patient, a 2.5 mL venous blood sample was collected into a 
PAXgene Blood RNA tube IVD (PreAnalytix), which was stored 
Table 1 Baseline patient characteristics in CD8 T cell cohort
CD uC
IbD1 (n=33) IbD2 (n=33) P value IbD1 (n=24) IbD2 (n=28) P value
Age (years) 30.3 (25.3–36.1) 30.3 (23.2–38.7) 0.98 43.8 (30.9–50.4) 40.5 (29.1–54.0) 0.92
Gender (% male) 14 (42.4%) 13 (39.4%) 1.00 13 (54.2%) 13 (46.4%) 0.78
Current smoker 10 (28.6%) 12 (33.3%) 0.79 1 (4.2%) 0 (0%) 0.46
Newly diagnosed 27 (81.8%) 24 (72.7%) 0.56 15 (62.5%) 20 (71.4%) 0.56
Disease duration (years) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.78 0.0 (0.0–2.2) 0.0 (0.0–3.6) 0.76
Haemoglobin (g/L) 12.5 (11.7–13.3) 13.1 (11.8–13.6) 0.63 14.0 (12.8–14.4) 13.0 (12.3–14.6) 0.26
CRP (mg/L) 26 (16–39) 25 (10–59) 0.60 6 (3–23) 4 (2–21) 0.26
Albumin (g/L) 35 (32–37) 37 (34–39) 0.14 39 (37–41) 39 (37–41) 0.96
Disease distribution:
  CD – L1 (ileal) 9 (27.3%) 13 (39.4%) 0.43 – – – 
  CD – L2 (ileocolonic) 11 (33.3%) 9 (27.3%) 0.79 – – – 
  CD – L3 (colonic) 13 (39.4%) 11 (33.3%) 0.80 – – – 
  CD – L4 (upper GI) 2 (6.1%) 3 (9.1%) 1.00 – – – 
  Perianal 6 (18.2%) 3 (9.1%) 0.48 – – – 
  UC – E1 (proctitis) – – – 5 (20.8%) 8 (28.6%) 0.75
  UC – E2 (left sided) – – – 9 (37.5%) 11 (39.3%) 1.00
  UC – E3 (extensive) – – – 10 (41.7%) 9 (32.1%) 0.57
Prospective follow-up (years) 4.9 (3.6–7.4) 5.3 (4.3–8.3) 0.24 5.6 (3.6–7.1) 5.5 (2.4–8.4) 0.54
Data shown in parentheses indicate median (IQR) for continuous variables or percentages for dichotomous variables. Statistical significance was calculated using a Mann-
Whitney test (two tailed) for continuous variables and Fisher’s exact test (two tailed) for dichotomous variables. Disease distribution was classified according to the Montreal 
Classification.27
CD, Crohn’s disease; CRP, C reactive protein.
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at −80°C. RNA was subsequently extracted, quantified and 
quality checked as described above. qPCR was performed for 
the 15 informative and 2 reference genes within the optimal 
classifier using Research-Use-Only PredictSURE IBD kits 
(PredictImmune) to determine whether patients were IBDhi 
or IBDlo. The clinical course experienced by the IBDhi and 
IBDlo subgroups was compared using prospectively collected 
phenotype data. Importantly, the phenotyping collection was 
blinded to the classifier designation and vice versa. All partici-
pants provided written informed consent.
statistical analysis
Statistical tests performed during microarray analysis or machine 
learning are described in the relevant sections. Survival analyses 
for time-to-first-treatment-escalation were performed using a 
log-rank test. Comparison of the number of treatment escala-
tions was performed using a Mann-Whitney test (two tailed for 
CD8 T cell analyses and one tailed for validation cohort anal-
yses). Comparison of the clinical and laboratory data in IBD1/
IBD2 patients was performed using Fisher’s test for dichot-
omous variables or Mann-Whitney test for continuous vari-
ables (two tailed). The α value for these analyses was 0.05. All 
statistical analyses and reporting were performed in accordance 
with Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines.25
resulTs
Whole blood classifier development
We have previously reported that a prognostic biomarker based 
on IBD1/IBD2 subgroup membership would represent a useful 
clinical tool, given its performance characteristics.12 Nonethe-
less, it is clear that any assay that requires CD8 T cell purifica-
tion and microarray analysis would be difficult to translate to 
clinical practice. For this reason, we investigated whether we 
could identify the same patient subgroups using whole blood, 
without the need for cell separation (figure 1A). To do this, we 
first defined a training cohort of 69 patients (39 CD, 30 UC; 35 
IBD1, 34 IBD2) for whom we had both CD8 T cell transcrip-
tomic data and a whole blood PAXgene Blood RNA sample (the 
latter taken at the same time as the CD8 T cell sample). Fifty 
of these patients were in our original report of IBD1/IBD212 
and 19 were recruited subsequently. RNA was extracted from 
PAXgene Blood RNA tubes, and genome-wide gene expression 
Figure 1 Development of a qPCR-based whole blood prognostic biomarker. (A) Schematic depicting the workflow for the development, optimisation 
and validation of the whole blood qPCR-based classifier with separate training and validation cohorts. (B) Distribution of correlation coefficients 
between microarray and qPCR-based measurements of gene expression for 39 genes. (C) Confidence of assignments to IBD1 and IBD2 subgroups in 
the training cohort using the qPCR classifier (15 informative and 2 reference genes). Colours indicate actual IBD1/IBD2 assignments based on CD8 
T cell transcriptomic analysis (red=IBD1, blue=IBD2). Inset summary table depicts results using 0.5 cut-off for group assignment. CD, Crohn’s disease.
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was measured by microarray (Affymetrix Human Gene 2.0 ST 
arrays). The resulting raw data were preprocessed to create a 
normalised dataset that could be used for classifier development 
(Materials and methods). To identify a whole blood classifier, we 
used a machine learning method (logistic regression with adap-
tive Elastic-Net penalisation21) to identify models comprising the 
smallest number of most predictive genes with least redundancy. 
A series of potential models were produced (online supplemen-
tary table 1) of which the optimal model comprised 12 genes and 
resulted in accurate identification of the IBD1/IBD2 subgroups 
(p=1.6×10−7 for comparison with a ‘dummy’ classifier using 
a binomial distribution of samples). The generalisation error 
for this model was estimated using LOOCV (accuracy=0.81, 
95% CI 0.70 to 0.90).
qPCr classifier development and optimisation
To translate this result into a clinically useful tool, we examined 
the top models and selected 39 candidate genes and 3 reference 
genes for qPCR optimisation (figure 1A, online supplementary 
table 2, Materials and methods). Of the candidate genes, 12 
were members of the optimal microarray-based classifier, 6 were 
highly correlated with genes in the optimal classifier and 21 were 
selected from adaptive Elastic-Net models with lower BIC (online 
supplementary table 2). Genes that showed poor correlation 
with microarray data were excluded (n=6, figure 1A,B). Using 
qPCR data, we then applied a similar statistical learning strategy 
(Materials and methods) to identify the optimal classifier (15 
informative and 2 reference genes; figure 1C, online supplemen-
tary table 3), which was locked down for further testing.
qPCr classifier validation
A critical step in the development of any new biomarker is inde-
pendent validation, in which the assay can be tested on samples 
that were not included in the discovery phase. This facilitates an 
assessment of whether the model will generalise to populations 
other than the one on which it was developed (figure 1A) and 
provides a more accurate estimate of the true performance char-
acteristics of the assay. We therefore tested the qPCR classifier 
in the validation cohorts of patients with CD and UC. When 
applied to these independent samples, the classification algo-
rithm assigned every patient into either the ‘IBDhi’ (analogous 
to IBD1) or ‘IBDlo’ (analogous to IBD2) subgroup. In both the 
CD and UC validation cohorts, patients in the IBDhi and IBDlo 
subgroups experienced very different disease courses. Patients 
in the IBDhi subgroup had consistently more aggressive disease, 
which was characterised by the need to escalate treatment earlier 
(with immunomodulators, biological therapies or surgery) 
and more frequently than for patients in the IBDlo subgroup 
(figure 2A–F). In the CD validation cohort, the HR for the differ-
ence in time to first escalation was 2.65 (95% CI 1.32 to 5.34; 
p=0.006) and in the UC validation cohort this HR was 3.12 
(95% CI 1.25 to 7.72; p=0.015) (figure 2A,B). Moreover, irre-
spective of the underlying disease, IBDhi patients experienced a 
disease course that necessitated more potent therapies to achieve 
disease remission (figure 2C,D). The sensitivity and specificity 
for predicting the need for multiple escalations within the first 
18 months were 72.7% and 73.2% in CD and 100% and 48% 
in UC. Of note, the relatively low specificity in UC reflects the 
lower treatment escalation rate observed (36 escalations in the 
UC validation cohort compared with 67 in the CD cohort) and 
thus while all of the UC patients who required multiple esca-
lations were IBDhi, not all of the IBDhi patients had required 
multiple escalations within the first 18 months. Importantly, 
because this test would be used at diagnosis, negative prediction 
(ie, correctly identifying patients who do not need additional 
therapy) is more relevant,26 both to improve resource alloca-
tion and not miss a ‘window of opportunity’ to optimally treat 
patients with progressive disease. In these validation cohorts, 
the negative predictive value for predicting multiple escalations 
within the first 18 months was high: 90.9% in CD and 100% 
in UC (figure 2E,F). These results are particularly noteworthy 
given that the classifier was developed to predict IBD1/IBD2 
subgroup membership (being directly assessed against this in the 
training cohort). In the validation cohorts, however, CD8 T cell 
transcriptomic data—and thus IBD1/IBD2 subgroup member-
ship—was not available, and so the biomarker had to be assessed 
against the difference in prognosis that was observed in the 
IBD1/IBD2 subgroups. This is one step removed from how the 
classifier was developed and represents a more difficult bench-
mark but is ultimately what a prognostic biomarker would need 
to predict to be clinically useful.
To facilitate translation of this test to clinical practice, analyt-
ical validation was also performed to assess precision, limit of 
detection, linearity, input RNA range and freeze/thaw cycling for 
each gene’s qPCR assay and for the combined multianalyte-de-
rived risk score (data not shown). The contribution of specific 
sources (eg, operator and batch) to the total assay variance was 
also assessed (data not shown). Together, these analytical and 
clinical validation data have resulted in a CE-marked assay that is 
ready for clinical use (PredictSURE IBD, PredictImmune).
Clinical phenotype over time
It is clear that the phenotypic consequences of IBDhi/IBDlo 
subgroup membership mirror those observed in IBD1/IBD2 
patients.12 However, due to their prospective collection, both of 
these cohorts had relatively limited follow-up (validation cohort: 
median 1.9 years; original CD8 T cell cohort manuscript12: 
median 1.6 years). To better understand the longer term conse-
quences of being in the IBD1 (IBDhi) or IBD2 (IBDlo) subgroups, 
we examined the extended phenotyping data from all patients 
for whom CD8 T cell gene expression data were available. This 
cohort was now larger than previously reported12 (sample size 
increased from 67 to 118) and had substantially longer follow-up 
(median follow-up increased from 1.6 years to 5.3 years). These 
increases in cohort size and follow-up enabled us to perform 
a more detailed analysis of the clinical consequences of IBD1/
IBD2 subgroup membership. Baseline patient characteristics 
are presented in table 1. Consistent with our previous findings, 
all patients could be readily classified into IBD1 or IBD2 based 
on CD8 T cell gene expression. There were no clinical charac-
teristics at baseline that distinguished between these subgroups 
(table 1), and specifically there was no correlation between 
measures of inflammation and subgroup membership.
Disease course in IbD1/IbD2 patients
CD: 66 patients with CD were recruited of whom 51 (77.3%) 
were newly diagnosed at enrolment. Thirty-three patients 
were in IBD1 and 33 in IBD2. Compared with patients in the 
IBD2 subgroup, IBD1 patients had a significantly shorter time 
to requiring a treatment escalation, as previously reported12 
(figure 3A). Interestingly, neither clinical parameters (any two 
of: steroid requirement, age <40 years and perianal disease) nor 
severe endoscopic features (including deep and extensive ulcer-
ation in at least one colonic segment) were able to predict the 
need for early treatment escalation (figure 3B,C). Indeed, even 
if we attempted to incorporate these, or other, clinical features 
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Figure 2 Validation of qPCR-based classifier in independent cohorts. (A and B) Kaplan-Meier plots of escalation-free survival for the CD validation 
cohort (A; n=66) and the UC validation cohort (B; n=57) as stratified by the IBDhi (IBD1 equivalent) and IBDlo (IBD2 equivalent) patient subgroups. 
Data are censored at 18 months. Statistical significance assessed by log-rank test. (C and D) Stacked density plots demonstrating the maximum 
medical therapy that was required during the first 2.5 years’ prospective follow-up of the IBDhi and IBDlo subgroups in CD (C) and UC (D). Treatments 
were plotted hierarchically (no treatment<immunomodulator<anti-TNFα<second-line biologicals (vedolizumab or ustekinumab) in CD and 5-ASA 
only<immunomodulator<anti-TNFα<vedolizumab < colectomy in UC). Arrows represent episodes of surgery that were required for CD patients 
at the indicated timepoints. Data are censored accordingly to length of follow-up so that the denominator is the total available cohort at each 
timepoint. (E and F) Forest plots of the relative risk (IBDhi vs IBDlo) of requiring no treatment escalations, one treatment escalation or two or more 
treatment escalations within the first 18 months after enrolment for patients with CD (E) and patients with UC (F). Relative risk is with respect to the 
IBDhi subgroup in each disease and is presented separately for the training cohort, validation cohort and combined cohorts. Error bars indicate 95% 
CIs. CD, Crohn’s disease.
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Figure 3 The clinical course of Crohn’s disease (CD) is different in IBD1 and IBD2 patients. (A) Kaplan-Meier plot of escalation-free survival for CD 
patients in the IBD1 and IBD2 subgroups. Data are censored at 18 months. Statistical significance assessed by log-rank test. (B and C) Kaplan-Meier 
plots in the same format as figure part A with patients subdivided according to clinical risk (high risk=2 or more of: age <40 years at diagnosis, early 
need for steroids and perianal disease; B) and presence of severe features at index endoscopy (deep and extensive ulceration in at least one colonic 
segment or endoscopist’s global assessment; C). (D) Stacked density plots demonstrating the maximum medical therapy that was required during 
5 years’ prospective follow-up in the IBD1 and IBD2 subgroups. Treatments were plotted hierarchically (no treatment<immunomodulator<anti-
TNFα<second-line biologicals (vedolizumab or ustekinumab)). Arrows represent episodes of surgery that were required at the indicated timepoints 
(of note one operation that is indicated in online supplementary table 4—in an IBD1 patient—occurred after 5 years and is not shown). Data are 
censored accordingly to length of follow-up so that the denominator is the total available cohort at each timepoint. (E) Disease course of individual 
CD patients (dotted lines). The colour of dotted lines reflects subgroup designation. Statistical significance was determined using a Mann-Whitney 
test.
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into a predictive classifier (using a Cox proportional hazards 
model), we found that none of them were able to improve the 
performance of the transcriptional classifier (data not shown).
IBD1 patients with CD also required significantly more 
treatment escalations over time due to persistently relapsing or 
chronically active disease (figure 3D,E). Indeed, in IBD1, the 
Figure 4 The clinical course of UC is different in IBD1 and IBD2 patients. (A) Kaplan-Meier plot of escalation-free survival for UC patients in the 
IBD1 and IBD2 subgroups. Data are censored at 18 months. Statistical significance assessed by log-rank test. (B) Kaplan-Meier plot in the same format 
as figure part A with patients subdivided according to endoscopic disease severity at index colonoscopy. P value calculated by comparing mild and 
severe cases. (C) Stacked density plots demonstrating the maximum medical therapy that was required during the first 5 years’ prospective follow-
up in the IBD1 and IBD2 subgroups. Treatments were plotted hierarchically (5-ASA only<immunomodulator<anti-TNFα<vedolizumab<colectomy). 
Data are censored accordingly to length of follow-up so that the denominator is the total available cohort at each timepoint. (D) Disease course of 
individual UC patients (dotted lines). The colour of dotted lines reflects subgroup designation. Statistical significance was determined using a Mann-
Whitney test.
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relative risk (RR) of requiring escalation to biologic therapy 
(excluding those who received biologic therapy due to immu-
nomodulator intolerance) was 3.0 (12/33 IBD1 patients, 4/33 
IBD2 patients) (online supplementary table 4). Likewise, the RR 
of not requiring any medical therapy in IBD1 was 0.53 (8/33 
IBD1 patients, 15/33 IBD2 patients) (figure 3E, online supple-
mentary table 4). Total surgery rates were not significantly 
different between the groups (10/33 IBD1, 7/33 IBD2), but the 
trend to a higher surgery rate in IBD1 mirrored that observed in 
the CD validation cohort (figure 2C) and so may simply reflect 
a lack of power to detect an effect. Notably, all of the patients 
who required a panproctocolectomy were in the IBD1 subgroup 
(online supplementary table 4). There were two deaths during 
follow-up: an IBD2 patient died from end-stage COPD and an 
IBD1 patient died from liver failure secondary to PSC.
UC: 52 patients with UC were recruited, of whom 35 (67.3%) 
were newly diagnosed. Twenty-four patients were in IBD1 and 
28 in IBD2. As in the CD cohort, UC patients in the IBD1 
subgroup experienced more aggressive disease with significantly 
earlier need for treatment escalation (figure 4A). Notably, endo-
scopic severity at baseline28 did not predict need for treatment 
escalation (figure 4B). Over time, IBD1 patients also required 
significantly more escalations due to recurrently active disease 
(figure 4C,D). There were several other similarities between the 
UC and CD cohorts, with the probability of not needing any treat-
ment escalations in IBD1 UC patients being approximately half 
that of IBD2 UC patients (RR=0.45), and the RR of requiring 
escalation to biological therapy or colectomy in IBD1 being 4.08 
(7/24 IBD1 patients, 2/28 IBD2 patients) (figure 4C,D, online 
supplementary table 4). Indeed, across all of the patient cohorts 
(CD8 T cell and whole blood) colectomies were only required 
in IBD1/IBDhi patients (7/56 IBD1 or IBDhi patients; 0/48 IBD2 
or IBDlo patients, p=0.01, two-tailed Fisher’s test). There was 
one death during follow-up: an IBD1 patient who was due to 
start anti-TNFα therapy for chronically active disease died from 
a pulmonary embolism.
DIsCussIOn
A major barrier to personalised medicine in CD and UC is the 
lack of biomarkers to guide treatment from diagnosis. Indeed, 
the performance requirements for a prognostic test mean that 
even though several parameters have been associated with 
prognosis in CD—including clinical features,29 serology30 and 
genetic variants31—none are sufficient to guide therapy in clin-
ical practice. Accordingly, current treatment regimens tend to 
adopt a ‘one-size-fits-all’ approach, which cannot provide safe, 
effective and cost-efficient therapy for every patient. Here, we 
describe the development of a practical, whole blood assay that 
is in direct response to this unmet need. This assay is the first 
prognostic test in IBD that has validated performance charac-
teristics that can support its use as a prognostic biomarker from 
diagnosis. Indeed, the performance characteristics of the qPCR 
classifier in both CD and UC are similar to that of existing 
gene expression-based in vitro diagnostic tests in oncology. For 
example, the HR for OncotypeDX, a gene expression diag-
nostic that predicts breast cancer recurrence,32 is 2.81 (95% CI 
1.70 to 4.64).33 Importantly, the proven benefit of early aggres-
sive therapy in IBD9 10 should only amplify the clinical benefit 
of using this assay to stratify patients at diagnosis, since IBDhi 
patients typically experience the sort of aggressive disease that 
should benefit most from early use of potent therapy. Collec-
tively, these data support the early adoption of this assay in clin-
ical practice, which should not be logistically difficult since a 
whole blood qPCR assay can be readily incorporated into stan-
dard laboratory protocols.
There are several limitations of this work. First, the study was 
non-interventional, and all patients were assessed and treated 
at the discretion of their gastroenterologists in accordance with 
national and international guidelines, rather than following a 
formal protocol. This, however, represents real-world practice 
and is the setting in which the test will ultimately be used. Second, 
because patients were recruited before induction therapy, we do 
not yet know how the biomarker would perform if treatment 
had already been started. Nonetheless, if induction therapy was 
underway, the biomarker could still be used if/when patients 
next re-flare, since the CD8 T cell signature is readily detect-
able during active disease.13 Clarifying the effect of concomi-
tant therapy is the subject of ongoing work. Third, while the 
performance characteristics of this assay meet the requirements 
of a useful prognostic biomarker, we have not yet conducted an 
interventional study to confirm that stratifying therapy using this 
biomarker would improve clinical outcomes. For this reason, 
we have concurrently designed a biomarker-stratified trial34 to 
test whether this assay can deliver personalised therapy from 
diagnosis. This trial (Predicting outcomes for Crohn’s DIsease 
using a molecular biomarker; www. crohnsprofiletrial. com) is 
currently recruiting in the UK and represents one of the first 
biomarker-stratified trials in any inflammatory disease. It will 
assess the relative benefit of ‘Top Down’ therapy (anti-TNFα 
and an immunomodulator) over ‘Accelerated Step-Up’ therapy 
in IBDhi and IBDlo patients to determine whether the biomarker 
can accurately match patients to the most appropriate treatment 
for them, thereby improving outcomes by optimising disease 
control and minimising drug toxicity.
In summary, we have developed, optimised and validated a 
whole blood gene expression biomarker that can predict prog-
nosis in patients with either CD or UC. This provides a rational 
basis for personalised therapy in IBD and represents an important 
step towards precision medicine for patients with CD or UC.
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Figure 1 Development of a qPCR-based whole blood prognostic biomarker. (A) Schematic depicting the 
workflow for the development, optimisation and validation of the whole blood qPCR-based classifier with 
separate training and validation cohorts. (B) Distribution of correlation coefficients between microarray 
and qPCR-based measurements of gene expression for 39 genes. (C) Confidence of assignments to IBD1 
and IBD2 subgroups in the training cohort using the qPCR classifier (15 informative and 2 reference 
genes). Colours indicate actual IBD1/IBD2 assignments based on CD8 T cell transcriptomic analysis 
(red=IBD1, blue=IBD2). Inset summary table depicts results using 0.5 cut-off for group assignment. CD, 
Crohn’s disease.
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Figure 2 Validation of qPCR-based classifier in independent cohorts. (A and B) Kaplan-Meier plots of 
escalation-free survival for the CD validation cohort (A; n=66) and the UC validation cohort (B; n=57) 
as stratified by the IBDhi (IBD1 equivalent) and IBDlo (IBD2 equivalent) patient subgroups. Data are 
censored at 18 months. Statistical significance assessed by log-rank test. (C and D) Stacked density plots 
demonstrating the maximum medical therapy that was required during the first 2.5 years’ prospective 
follow-up of the IBDhi and IBDlo subgroups in CD (C) and UC (D). Treatments were plotted hierarchically 
(no treatment<immunomodulator<anti-TNFα<second-line biologicals (vedolizumab or ustekinumab) in 
CD and 5-ASA only<immunomodulator<anti-TNFα<vedolizumab < colectomy in UC). Arrows represent 
episodes of surgery that were required for CD patients at the indicated timepoints. Data are censored 
accordingly to length of follow-up so that the denominator is the total available cohort at each timepoint. 
(E and F) Forest plots of the relative risk (IBDhi vs IBDlo) of requiring no treatment escalations, one 
treatment escalation or two or more treatment escalations within the first 18 months after enrolment for 
patients with CD (E) and patients with UC (F). Relative risk is with respect to the IBDhi subgroup in each 
disease and is presented separately for the training cohort, validation cohort and combined cohorts. Error 
bars indicate 95% CIs. CD, Crohn’s disease.
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Figure 3 The clinical course of Crohn’s disease (CD) is different in IBD1 and IBD2 patients. (A) Kaplan-
Meier plot of escalation-free survival for CD patients in the IBD1 and IBD2 subgroups. Data are censored 
at 18 months. Statistical significance assessed by log-rank test. (B and C) Kaplan-Meier plots in the same 
format as figure part A with patients subdivided according to clinical risk (high risk=2 or more of: age 
<40 years at diagnosis, early need for steroids and perianal disease; B) and presence of severe features 
at index endoscopy (deep and extensive ulceration in at least one colonic segment or endoscopist’s 
global assessment; C). (D) Stacked density plots demonstrating the maximum medical therapy that was 
required during 5 years’ prospective follow-up in the IBD1 and IBD2 subgroups. Treatments were plotted 
hierarchically (no treatment<immunomodulator<antiTNFα<second-line biologicals (vedolizumab or 
ustekinumab)). Arrows represent episodes of surgery that were required at the indicated timepoints (of 
note one operation that is indicated in online supplementary table 4—in an IBD1 patient—occurred after 
5 years and is not shown). Data are censored accordingly to length of follow-up so that the denominator 
is the total available cohort at each timepoint. (E) Disease course of individual CD patients (dotted lines). 
The colour of dotted lines reflects subgroup designation. Statistical significance was determined using a 
Mann-Whitney test.
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Figure 4 The clinical course of UC is different in IBD1 and IBD2 patients. (A) Kaplan-Meier plot 
of escalation-free survival for UC patients in the IBD1 and IBD2 subgroups. Data are censored at 18 
months. Statistical significance assessed by log-rank test. (B) Kaplan-Meier plot in the same format as 
figure part A with patients subdivided according to endoscopic disease severity at index colonoscopy. 
P value calculated by comparing mild and severe cases. (C) Stacked density plots demonstrating the 
maximum medical therapy that was required during the first 5 years’ prospective followup in the IBD1 
and IBD2 subgroups. Treatments were plotted hierarchically (5-ASA only<immunomodulator<anti-
TNFα<vedolizumab<colectomy). Data are censored accordingly to length of follow-up so that the 
denominator is the total available cohort at each timepoint. (D) Disease course of individual UC patients 
(dotted lines). The colour of dotted lines reflects subgroup designation. Statistical significance was 
determined using a MannWhitney test.
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